Seller record · Telehealth service

Alan Meds

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: The site names no filling pharmacy. The terms say a prescription is matched with one of the partner pharmacies, and the product pages say only a compounding pharmacy or a US-accredited pharmacy. 1 more criterion also fails; see the table below.

At a glance

Alan MedsTelehealth service

6/8criteria passed

Price: Tirzepatide $325 a month prepaid for 6 months, semaglutide $158 on a buy one get one offer (struck-through $315)
Sells: compounded semaglutide, compounded tirzepatide, and 11 more
FDA letters: 1 on file

Visit Alan Meds See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling compounded semaglutide and tirzepatide injections, oral and microdose GLP-1 programs, oral sermorelin, NAD+ and glutathione, plus consultations for Wegovy, Zepbound, Ozempic and Mounjaro. Its prices are monthly figures paid upfront on multi-month plans, it names no filling pharmacy, and it was named in an FDA warning letter in February 2026.

Operating entity Alan Health Technologies, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Alan Meds' personalized compounded semaglutide product page; Alan Meds' website
S2	Prescription gating	PASS	Alan Meds' personalized compounded semaglutide page on its health storefront; Alan Meds' personalized compounded semaglutide product page
S3	Pharmacy identification	FAIL	Alan Meds' terms and conditions; Alan Meds' personalized compounded semaglutide product page
S4	Compounding disclosure	PASS	Alan Meds' personalized compounded semaglutide product page; Alan Meds' oral sermorelin product page
S5	Analytical documentation	FAIL	Alan Meds' oral compounded GLP-1 product page; Alan Meds' support page
S6	Business address	PASS	Alan Meds' terms and conditions
S7	Price disclosure	PASS	Alan Meds' personalized compounded semaglutide product page; Alan Meds' personalized compounded tirzepatide product page; Alan Meds' oral sermorelin product page; Alan Meds' NAD+ injection product page
S8	Enforcement status	PASS	fda.gov; letter 721814

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed physician designs the treatment plan only if a prescription is appropriate, through the independently owned physician networks the footer names, MDI Medical Group, P.C. and Alan Medical Group P.C.Source: Alan Meds' personalized compounded semaglutide product page; Alan Meds' website.

S2PASSEvery get started button opens an initial intake that asks which treatments the patient is eligible for, and the product pages carry no cart. Medication ships only after the patient is approved and deemed eligible for a prescription.Source: Alan Meds' personalized compounded semaglutide page on its health storefront; Alan Meds' personalized compounded semaglutide product page.

S3FAILThe site names no filling pharmacy. The terms say a prescription is matched with one of the partner pharmacies, and the product pages say only a compounding pharmacy or a US-accredited pharmacy.Source: Alan Meds' terms and conditions; Alan Meds' personalized compounded semaglutide product page.

S4PASSCompounded medications are not FDA-approved, printed beneath the price on every compounded product page, and the answers say compounded drugs are not subject to FDA approval.Source: Alan Meds' personalized compounded semaglutide product page; Alan Meds' oral sermorelin product page.

S5FAILNo certificate of analysis or lot document is published. The product pages and the answers say each batch is tested by partner pharmacies, and no report is linked.Source: Alan Meds' oral compounded GLP-1 product page; Alan Meds' support page.

S6PASSAlan Health Technologies Inc. at 249 Smith St. PMB 3008, Brooklyn NY 11231, a private mailbox as the PMB number shows, printed in the terms as the address for notice.Source: Alan Meds' terms and conditions.

S7PASSCompounded semaglutide at $158 a month paid upfront on a 2-month plan under a buy one month, get one month free promotion, beside a struck-through $315. Compounded tirzepatide at $325 a month paid upfront on a 6-month plan, oral sermorelin at $199 a month on a 3-month plan beside a struck-through $295, the NAD+ injection at $235 a month on a 2-month plan and the glutathione injection at $155 a month on a 6-month plan.Source: Alan Meds' personalized compounded semaglutide product page; Alan Meds' personalized compounded tirzepatide product page; Alan Meds' oral sermorelin product page; Alan Meds' NAD+ injection product page.

S8PASSFDA warning letter 721814, February 2026, names Alan Health Technologies Inc. dba Alan at 249 Smith St., PMB 3008, Brooklyn, NY 11231, alleging that its compounded semaglutide and tirzepatide are misbranded because the pictured labels suggest Alan is the compounder. No close-out letter appears in the index. No FDA action has halted the business, and the seller continues to operate.Source: fda.gov; letter 721814.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, oral compounded semaglutide, microdose compounded tirzepatide and oral semaglutide, oral compounded sermorelin, NAD+ injection, nasal spray, patches and face cream, glutathione injection, nasal spray and patches, Wegovy, Zepbound, Ozempic, Mounjaro, B12 and MIC injections, metformin.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells glutathione

Enforcement documents on file: 1 warning letter

FDA warning letter 721814, issued February 2026, to Alan Health Technologies Inc. dba AlanThe pictured labels on Alan Meds' website suggest Alan is the compounder of its compounded semaglutide and tirzepatide when it is not, which is false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Unpaid link. Alan Meds does not pay the site, and nothing is earned when it is used. Funding.

Visit Alan Meds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.